Table 5.

Incidence of COVID-19 outcomes in PS-matched Ibu and Comp cohorts

Comparisons	Database	Persons each cohorta	Cases		Follow-up (years)		Incidence (%)		Incidence (per 1k person-years)
			Ibu	Comp	Ibu	Comp	Ibu	Comp	Ibu	Comp
COVID-19 diagnosis (Nov 2019–Jan 2020)
Ibu vs COX-2i	PharMetrics Plus	39,572	156	480	6931	14,539	0.39	1.21	22.5	33.0
Ibu vs COX-2i	OpenClaims	272,097	1407	3432	62,849	138,466	0.52	1.26	22.4	24.8
Ibu vs ns-NSAIDs	PharMetrics Plus	69,723	174	449	9038	16,081	0.25	0.64	19.3	27.9
Ibu vs ns-NSAIDs	OpenClaims	563,839	1885	4100	98,946	168,055	0.33	0.73	19.1	24.4
Ibu vs paracetamol	PharMetrics Plus	54,074	119	414	6830	10,454	0.22	0.77	17.4	39.6
Ibu vs paracetamol	OpenClaims	437,928	1334	4523	71,973	141,905	0.30	1.03	18.5	31.9
COVID-19 diagnosis (Feb 2020–Oct 2020)
Ibu vs COX-2i	PharMetrics Plus	67,190	532	1247	10,894	21,898	0.79	1.86	48.8	57.0
Ibu vs COX-2i	OpenClaims	457,280	3551	7370	92,004	193,931	0.78	1.61	38.6	38.0
Ibu vs ns-NSAIDs	PharMetrics Plus	120,954	689	1334	14,424	24,796	0.57	1.10	47.8	53.8
Ibu vs ns-NSAIDs	OpenClaims	943,006	5382	9682	143,309	241,999	0.57	1.03	37.6	40.0
Ibu vs paracetamol	PharMetrics Plus	101,635	575	834	11,617	15,820	0.57	0.82	49.5	52.7
Ibu vs paracetamol	OpenClaims	776,963	4325	8106	110,110	188,659	0.56	1.04	39.3	43.0
Hospitalised with COVID-19 (Nov 2019–Jan 2020)
Ibuprofen vs COX-2i	PharMetrics Plus	39,572	29	89	6963	14,660	0.07	0.22	4.2	6.1
Ibuprofen vs COX-2i	OpenClaims	272,097	446	961	63,317	139,848	0.16	0.35	7.0	6.9
Ibuprofen vs ns-NSAIDs	PharMetrics Plus	69,723	24	91	9073	16,183	0.03	0.13	2.7	5.6
Ibuprofen vs ns-NSAIDs	OpenClaims	563,839	561	1171	99,526	169,551	0.10	0.21	5.6	6.9
Ibuprofen vs paracetamol	PharMetrics Plus	54,074	18	82	6854	10,565	0.03	0.15	2.6	7.8
Ibuprofen vs paracetamol	OpenClaims	437,928	386	1274	72,392	143,803	0.09	0.29	5.3	8.9
Hospitalised with COVID-19 (Feb 2020–Oct 2020)
Ibu vs COX-2i	PharMetrics Plus	67,190	112	211	10,979	22,153	0.17	0.31	10.2	9.5
Ibu vs COX-2i	OpenClaims	457,280	1044	1948	92,847	196,320	0.23	0.43	11.2	9.9
Ibu vs ns-NSAIDs	PharMetrics Plus	120,954	128	262	14,506	25,020	0.11	0.22	8.8	10.5
Ibu vs ns-NSAIDs	OpenClaims	943,006	1456	2432	144,396	244,609	0.15	0.26	10.1	9.9
Ibu vs paracetamol	PharMetrics Plus	101,635	120	185	11,687	16,004	0.12	0.18	10.3	11.6
Ibu vs paracetamol	OpenClaims	776,963	1143	2228	110,941	191,379	0.15	0.29	10.3	11.6

On-treatment incidence rates of COVID-19 diagnosis or hospitalisation with COVID-19 in Ibu vs Comp user cohorts. For each pairwise comparison, we report the PS-matched cohort size, follow-up years, the number of events and incidences

Comp comparator, COVID-19 coronavirus disease 2019, COX-2i cyclooxygenase-2 inhibitors, Ibu ibuprofen, ns-NSAIDs non-selective non-steroidal anti-inflammatory drugs, PS propensity sore

^aIbu and Comp cohorts are matched 1:1 on the PS and are therefore the same size